Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Francis Duhay Biography and Net Worth

Director of enVVeno Medical

Dr. Francis Duhay, a trained cardiac and thoracic surgeon, is the former Chief Medical Officer at Edwards Life Sciences, the world’s leader in heart valves, where he led medical and clinical affairs for transcatheter and surgical heart valves. While at Edwards, Dr. Duhay led the preparation and submission, and ultimate regulatory approval of two FDA Premarket Approval (PMA) applications for transcatheter and surgical heart valve therapies and was responsible for the design and execution of the applicable clinical trials. Dr. Duhay was also the Vice President and General Manager of the Ascendra™ transcatheter heart valve business unit at Edwards, where he grew the unit from sixteen to eighty employees and contributed to annual growth in sales from $3 million to $250 million. Dr. Duhay was also an industry representative and clinical expert, and member of the working group for ISO 5840, the international quality standard for the design, development, and testing of heart valves.

What is Francis Duhay's net worth?: The estimated net worth of Francis Duhay is at least $52,068.39 as of August 16th, 2022. Dr. Duhay owns 20,911 shares of enVVeno Medical stock worth more than $52,068 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Duhay may own. Learn More about Francis Duhay's net worth.
How do I contact Francis Duhay?: The corporate mailing address for Dr. Duhay and other enVVeno Medical executives is 70 DOPPLER, IRVINE CA, 92618. enVVeno Medical can also be reached via phone at (949) 261-2900 and via email at [email protected]. Learn More on Francis Duhay's contact information.
Has Francis Duhay been buying or selling shares of enVVeno Medical?: Francis Duhay has not been actively trading shares of enVVeno Medical within the last three months. Most recently, on Tuesday, August 16th, Francis Duhay bought 7,751 shares of enVVeno Medical stock. The stock was acquired at an average cost of $6.14 per share, with a total value of $47,591.14. Following the completion of the transaction, the director now directly owns 20,911 shares of the company's stock, valued at $128,393.54. Learn More on Francis Duhay's trading history.
Who are enVVeno Medical's active insiders?: enVVeno Medical's insider roster includes Robert Berman (CEO), Francis Duhay (Director), Marc Glickman (SVP), Robert Gray (Director), and Matthew Jenusaitis (Director). Learn More on enVVeno Medical's active insiders.
Are insiders buying or selling shares of enVVeno Medical?: In the last year, insiders at the sold shares 1 times. They sold a total of 8,334 shares worth more than $51,837.48. The most recent insider tranaction occured on March, 13th when CTO Hamed Alavi sold 8,334 shares worth more than $51,837.48. Insiders at enVVeno Medical own 16.0% of the company. Learn More about insider trades at enVVeno Medical.
Information on this page was last updated on 3/13/2024.

Francis Duhay Insider Trading History at enVVeno Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/16/2022	Buy	7,751	$6.14	$47,591.14	20,911
5/17/2021	Buy	9,492	$5.33	$50,592.36	13,160

Francis Duhay Buying and Selling Activity at enVVeno Medical

enVVeno Medical Company Overview

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Today's Range

Now: $2.49

$2.45

$2.74

50 Day Range

MA: $3.22

$2.49

$3.65

2 Week Range

Now: $2.49

$2.45

$6.97

Volume

691,785 shs

Average Volume

112,245 shs

Market Capitalization

$43.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

This Indicator called BOTH NVDA rallies

From ProsperityPub | Ad

Click this link here.